Targeting fusions for improved outcomes in oncology treatment.

ABSTRACT:

Background

Fusions are increasingly pursued as oncology therapeutic targets. The current study evaluated differences in outcomes for fusion versus nonfusion targets.

Methods

Outcomes were compared for patients with fusions versus those with other alterations for US Food and Drug Administration-approved single agents (from package inserts) and for patients treated at the University of California at San Diego.

Results

A total of 28 drugs approved by the US Food and Drug Administration (6189 patients) were included in the analysis. The median response rate was 68% versus 50% for fusions versus nonfusion matches (odds ratio [OR], 1.67; P < .0001); solid tumor therapies had an OR of 2.07 (P < .0001) and hematologic therapies had an OR of 3.35 (P < .0001) for fusion versus

SUBMITTER: Nikanjam M 

PROVIDER: S-EPMC7050395 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature